X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SUN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SUN PHARMA GSK PHARMA/
SUN PHARMA
 
P/E (TTM) x 66.4 37.6 176.5% View Chart
P/BV x 13.4 4.0 333.0% View Chart
Dividend Yield % 2.2 0.3 685.0%  

Financials

 GSK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
SUN PHARMA
Mar-18
GSK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760701 394.0%   
Low Rs2,040433 470.9%   
Sales per share (Unadj.) Rs339.0110.4 307.1%  
Earnings per share (Unadj.) Rs41.411.0 377.3%  
Cash flow per share (Unadj.) Rs45.917.2 266.4%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %1.50.4 413.3%  
Book value per share (Unadj.) Rs242.9158.8 153.0%  
Shares outstanding (eoy) m84.702,399.26 3.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.15.1 137.9%   
Avg P/E ratio x57.951.6 112.2%  
P/CF ratio (eoy) x52.332.9 158.9%  
Price / Book Value ratio x9.93.6 276.8%  
Dividend payout %84.518.2 463.8%   
Avg Mkt Cap Rs m203,2801,360,021 14.9%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m5,23453,671 9.8%   
Avg. sales/employee Rs ThNM14,890.9-  
Avg. wages/employee Rs ThNM3,017.1-  
Avg. net profit/employee Rs ThNM1,480.6-  
INCOME DATA
Net Sales Rs m28,715264,895 10.8%  
Other income Rs m5458,388 6.5%   
Total revenues Rs m29,260273,282 10.7%   
Gross profit Rs m5,05956,081 9.0%  
Depreciation Rs m38014,998 2.5%   
Interest Rs m25,176 0.0%   
Profit before tax Rs m5,22244,295 11.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m178-9,505 -1.9%   
Tax Rs m1,8928,452 22.4%   
Profit after tax Rs m3,50826,338 13.3%  
Gross profit margin %17.621.2 83.2%  
Effective tax rate %36.219.1 189.9%   
Net profit margin %12.29.9 122.9%  
BALANCE SHEET DATA
Current assets Rs m21,815316,359 6.9%   
Current liabilities Rs m15,999198,643 8.1%   
Net working cap to sales %20.344.4 45.6%  
Current ratio x1.41.6 85.6%  
Inventory Days Days6495 67.1%  
Debtors Days Days19108 17.4%  
Net fixed assets Rs m12,475213,178 5.9%   
Share capital Rs m8472,399 35.3%   
"Free" reserves Rs m19,726378,606 5.2%   
Net worth Rs m20,573381,006 5.4%   
Long term debt Rs m617,721 0.0%   
Total assets Rs m39,475643,028 6.1%  
Interest coverage x2,612.09.6 27,327.3%   
Debt to equity ratio x00 0.6%  
Sales to assets ratio x0.70.4 176.6%   
Return on assets %8.94.9 181.4%  
Return on equity %17.16.9 246.7%  
Return on capital %26.210.0 261.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56440,816 1.4%   
Fx outflow Rs m7,42930,143 24.6%   
Net fx Rs m-6,86510,673 -64.3%   
CASH FLOW
From Operations Rs m4,72839,072 12.1%  
From Investments Rs m-1,042-33,708 3.1%  
From Financial Activity Rs m-3,066-15,393 19.9%  
Net Cashflow Rs m620-7,359 -8.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.1 198.8%  
FIIs % 23.8 23.0 103.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   102,036 133,026 76.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS